A Study to Measure Energy Expenditure and Food Intake in Participants With Obesity Using Tirzepatide
NCT04081337
Completed
This is a study of tirzepatide in participants with obesity. The main purpose is to learn more about how tirzepatide affects the number of calories participants burn and the amount of food they eat. The study lasted for 28 weeks and will include about 21 visits to the study center.
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
05/26/2023
Locations: Pennington Biomedical Research Center, Baton Rouge, Louisiana
Conditions: Obesity
Register for Updates
A Study of Tirzepatide (LY3298176) in Healthy Participants and Participants With Type 2 Diabetes (T2DM)
NCT02759107
Completed
The main purposes of this study are to determine: * The safety of tirzepatide and any side effects that might be associated with it. * How much tirzepatide gets into the bloodstream and how long it takes the body to get rid of it. * How tirzepatide affects the levels of blood sugar. This study includes 3 parts (A, B and C). Part A involves a single dose of tirzepatide taken as a subcutaneous (SC) injection just under the skin and will be approximately 10 weeks in duration, including screening.... Read More
Gender:
ALL
Ages:
Between 21 years and 70 years
Trial Updated:
04/17/2023
Locations: Miami Research Associates, South Miami, Florida +1 locations
Conditions: Healthy, Type 2 Diabetes Mellitus (T2DM)
Register for Updates
A Study to Measure Stomach Emptying in Overweight Non-diabetic and Diabetic Participants Using Tirzepatide
NCT04407234
Completed
The purpose of this study is to learn more about how tirzepatide affects stomach emptying in overweight/very overweight participants. Participants include those without diabetes and those with type 2 diabetes. The study will last about 13 weeks for each participant, including screening.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/11/2023
Locations: Clinical Pharmacology of Miami, Hialeah, Florida
Conditions: Overweight, Obesity, Diabetes Mellitus, Type 2
Register for Updates
A Study of Tirzepatide at Different Injection Sites in Participants With Different Body Sizes
NCT04050670
Completed
The purpose of this study is to compare the amount of tirzepatide that gets into the blood stream and how long it takes the body to get rid of it, when injected under the skin of the upper arm and thigh compared to the abdomen. The study will be conducted in healthy males and females with different body sizes. The tolerability of tirzepatide will be evaluated and information about any side effects experienced will be collected. For each participant, the study will last about 20 weeks, including... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
04/10/2023
Locations: Covance Clinical Research Inc, Daytona Beach, Florida
Conditions: Healthy
Register for Updates
A Study of Tirzepatide (LY3298176) in Participants With Impaired Kidney Function
NCT03482024
Completed
The purpose of this study is to assess how fast tirzepatide gets into the blood stream and how long it takes the body to remove it in participants with impaired kidney function compared to healthy participants.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
06/09/2022
Locations: Orange County Research Center, Tustin, California +3 locations
Conditions: Renal Insufficiency, End Stage Renal Disease
Register for Updates
A Study of Tirzepatide in Participants With Impaired Liver Function
NCT03940742
Completed
The purpose of this study is to assess how fast tirzepatide gets into the blood stream and how long it takes the body to remove it in participants with impaired liver function compared to healthy participants. The study will last about two months and will include five visits to the study center.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
06/09/2022
Locations: Orange County Research Center, Tustin, California +2 locations
Conditions: Hepatic Insufficiency
Register for Updates
A Study of the Effect of Tirzepatide on How the Body Handles Birth Control Pills in Healthy Female Participants
NCT04172987
Completed
The purpose of this study is to look at how the body processes the commonly prescribed birth control pill, ethinylestradiol + norgestimate (EE/NGM), in healthy female participants and the effect of tirzepatide on how EE/NGM is processed by the body. Information about any side effects that may occur will also be collected. Screening is required within 28 days prior to the start of the study. For each participant, the study will last about 20 weeks, including screening.
Gender:
FEMALE
Ages:
Between 18 years and 45 years
Trial Updated:
06/09/2022
Locations: Covance Dallas, Dallas, Texas
Conditions: Healthy
Register for Updates
A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk
NCT03730662
Completed
The purpose of the trial is to assess the efficacy and safety of tirzepatide taken once a week to insulin glargine taken once daily in participants with type 2 diabetes and increased cardiovascular risk. The study will last about 108 weeks and may include up to 30 visits.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/21/2022
Locations: Advanced Research Center, Anaheim, California +215 locations
Conditions: Type 2 Diabetes Mellitus
Register for Updates
A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes
NCT03987919
Completed
The reason for this study is to compare the effect of the study drug tirzepatide to semaglutide on blood sugar levels in participants with type 2 diabetes. The study will last approximately 47 weeks and may include about 12 visits.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/21/2022
Locations: Cahaba Research, Birmingham, Alabama +126 locations
Conditions: Type 2 Diabetes
Register for Updates
A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes
NCT03882970
Completed
The purpose of this study is to compare the effect of the study drug tirzepatide to insulin degludec on blood sugar levels in participants with type 2 diabetes. The study will last about 67 weeks and may include up to 22 visits.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/14/2022
Locations: Arkansas Clinical Research, Little Rock, Arkansas +121 locations
Conditions: Type 2 Diabetes Mellitus
Register for Updates
A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin
NCT04039503
Completed
The purpose of this study is to compare the safety and efficacy of the study drug tirzepatide to placebo in participants with type 2 diabetes that are already on insulin glargine, with or without metformin. Participants will administer tirzepatide or placebo along with their previous glucose lowering medications. The study will last approximately 47 weeks and may include about 23 visits.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/12/2021
Locations: Valley Endocrine, Fresno, Fresno, California +47 locations
Conditions: Type 2 Diabetes
Register for Updates
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone
NCT03954834
Completed
The goal for this study is to evaluate the efficacy and safety of tirzepatide versus placebo in participants with type 2 diabetes not under control with diet and exercise alone. The study will last approximately 47 weeks and may include about 15 visits.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/18/2021
Locations: National Research Institute, Huntington Park, California +52 locations
Conditions: Type 2 Diabetes Mellitus
Register for Updates